Back to catalogue
№ 063 25 filings · 2021-11-05 → 2026-04-23

BEAZLEY PLC

BEZ
Insurance Share price 1,309p Market cap £781bn Overall fit 260 /1000

A disciplined specialty insurer but not an AI receiver, with limited operating leverage and a share price driven by a live takeover offer rather than cheap fundamentals — poor fit for a strategy prioritising AI exposure, operating leverage and valuation discipline.

Fair value range 950p–1,350p Mid case · £6.9bn
Absolute upside -99.1% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean, well-disclosed Lloyd's segmental reporting
  • Consistent track record of meeting or beating own guidance
  • Well-understood IFRS 17 insurance accounting
Limits the call
  • Fair value depends on undisclosed takeover offer terms (2.7 Announcement referenced but not provided)
  • Standalone vs takeover-anchored valuations diverge by 20-30%
Methodology

Normalised earnings multiple blended with takeover-implied price

In one line · bull case

Disciplined Lloyd's specialty insurer trading at a takeover-anchored price with limited standalone upside; the live 2.7 offer is the dominant valuation driver.

In one line · biggest risk

If the current takeover offer breaks, the share price would likely retrace 20-30% toward the pre-rumour 800-950p range.

Drivers
AI beneficiary 25 /100
Cyber-insurance demand loosely linked to AI-era risk but value capture flows to security vendors; rates in NA cyber are falling, not rising.
Operating leverage 25 /100
Insurance costs scale broadly with premiums; no fixed-cost SaaS-like inflection — a revenue surprise produces proportionate profit, not multiples of it.
Earnings vs expectations 65 /100
Consistent delivery vs. own CoR guidance across 2022-25; upgraded 2025 CoR guide to low 80s from mid 80s.
Growth momentum 40 /100
Growth has decelerated from mid-20s net (2023) to low single digits (2025) as rates soften, especially in cyber.
Moat 55 /100
Market leader in cyber and specialty lines; strong Lloyd's franchise and multi-platform footprint, but low switching costs for brokers.
Earnings quality 65 /100
Clean reporting under IFRS 17; mark-to-market investment income can be noisy but underwriting results are high-quality.
Management quality 70 /100
CEO Adrian Cox has demonstrated cycle discipline, consistent guidance delivery and shareholder-friendly buybacks since 2024.
Cyclicality 65 /100
Lloyd's specialty insurance is cyclical with meaningful nat-cat and rate-cycle beta (Helene/Milton $125-175m; CA wildfire ~$80m).
Leverage 25 /100
Well-capitalised insurer with Solvency II ratio target >170%; A-rated balance sheet; standard sector gearing.
Value-trap signals · 4
  • Price almost entirely driven by takeover approach rather than fundamentals
  • Rate index deteriorating from +17% (2022) to -4% (2025)
  • 2022 emergency placing at 575p sits uneasily against current buyback and bid activity
  • Several AGM 2026 resolutions received <80% support, hinting at stakeholder tensions around the transaction

Beazley plc (BEZ) — Investment Research Note

Executive summary

Beazley is a Lloyd's-focused specialty insurer underwriting cyber, property, MAP, specialty and digital lines, with 2025 gross written premiums of $6.1bn and a diversified three-platform model (Lloyd's, US E&S, Ireland, with Bermuda now being built out). The trajectory over the covered period runs from a hard-market tailwind (2022-23 rate increases of 17-23%) into a clear 2024-25 inflection to a softening cycle, where the group has pivoted from premium-rate growth to combined-ratio discipline — delivering an upgraded "low 80s" undiscounted CoR guide for 2025 even as rates on renewal fell 4% 2025-11-25 trading update. The single most important point for valuation today is that Beazley is in play: the 2 March 2026 dividend announcement explicitly references a "2.7 Announcement" (the Takeover Code's firm-offer trigger), and the 22 April 2026 "Court and General meeting" and Form 8.3 disclosure from LMR Partners confirm a live offer process — the 47.8% one-year share-price move is almost entirely deal-driven, not fundamental.

Fair value estimate

  • Standalone (no deal) fair value: 950–1,150p per share (£5.7bn–£6.9bn mcap). Methodology: normalised earnings multiple. 2024 GWP $6.2bn, 2025 GWP $6.1bn, net premiums written ~$5bn, undiscounted CoR low 80s implies underwriting profit of ~$900m–$1,000m; investment income ~$600m on an $11.7bn book yielding ~4%; pre-tax ~$1.3-1.5bn, net ~£900m-£1,000m. EPS ~150–165p on ~600m shares. 7-8x multiple reflects (a) rate softening across most lines, (b) catastrophe-year reset risk, (c) elevated nat-cat beta.
  • Takeover-implied fair value: 1,250–1,350p (£7.5bn–£8.1bn mcap). The current 1,308.5p price trades essentially at an inferred deal level; the Nov 2025 pre-rumour trough was 797p, so the implied control premium is ~55-65%.
  • Vs. latest disclosed mcap of £7,808.5m: at the midpoint of the takeover-implied range the upside is approximately 0% (fair); vs. the standalone range the downside is ~20-30% if the deal collapses.
  • Absolute upside/downside: fair at bid levels; -20-30% without a deal.

Sector context

Classification confirmed: Financials / Insurance (Lloyd's specialty). Beazley's quality is above typical peers in the Lloyd's specialty cohort — class-leading cyber franchise, consistent CoR delivery, strong solvency and track record of returning capital via buybacks. Growth was above peers in 2022-23 (hard-market beneficiary); it is now in-line as the cycle softens. Listed peers include Hiscox (HSX), Lancashire (LRE) and Conduit Re (CRE); broader comparators are Chubb, Everest and RenRe.

Investment thesis (3 bullets)

  • Live takeover offer underpins the price. The 2 March 2026 "Permitted Dividend" reference to a 2.7 Announcement, plus the Court/General meeting held alongside the April 2026 AGM, confirm a firm offer process — the share price is anchored to deal economics rather than cyclical insurance multiples 2026-03-02 dividend declaration; 2026-04-23 AGM result.
  • Underwriting discipline through the softening cycle. Despite -4% rates in Q3 2025, Beazley upgraded its 2025 combined-ratio outlook to "low 80s" undiscounted and emphasised prioritising profitability over volume — demonstrating cycle-management credibility 2025-11-25 trading update.
  • Capital-light growth optionality via Bermuda. $500m of capital allocated to a new Bermuda platform targeting alternative risk transfer, which (if the deal breaks) extends the Lloyd's/E&S/Ireland platform strategy into higher-margin, less commoditised segments 2025-11-25 trading update.

Key risks (3 bullets)

  • Deal break risk. No deal terms are disclosed in the filings; shareholders at the April 2026 General Meeting expressed concern (several resolutions received <80% support, including a 42% vote against the LTIP, implying stakeholder tension around the transaction) — if the offer collapses, the share price would likely retrace toward the 800–950p pre-rumour range 2026-04-23 AGM result.
  • Rate softening and catastrophe exposure. Rates fell 4% in Q3 2025 (vs. +23% in Q3 2021), North American cyber remains "very competitive", and the group is directly exposed to hurricane and wildfire losses — $125-175m net from Helene/Milton in 2024 and ~$80m from California wildfires in Q1 2025 2024-11-06 and 2025-04-29 trading updates.
  • Cyber-market compression. The hardest-pricing franchise of 2021-23 is now the slowest-growing division (-8% YoY premium growth in Q3 2025, -6% rates); if NA cyber competitive dynamics worsen the group loses its primary growth engine 2025-11-25 trading update.

Operating leverage

Insurance economics are not a high operating-leverage model in the sense this strategy seeks. Beazley's cost base scales broadly with premiums — the vast majority of the P&L is claims, reinsurance, acquisition commissions and underwriting salaries, all of which flex with volume. The CoR of 80% implies a 20-point underwriting margin, but this margin is driven by risk selection and rate adequacy, not fixed-cost absorption. Investment income ($600m on an $11.7bn float yielding ~4%) is the main fixed-asset-like earnings stream, but it scales with reserves (which scale with premiums). A 10-20% revenue beat would deliver a broadly proportionate increase to operating profit, not a disproportionate one. There is no SaaS-like gross-margin inflection or capacity-constrained pricing-power dynamic to compound a positive surprise 2024-11-06 and 2025-11-25 trading updates.

Value-trap signals

  • Share price move is almost entirely corporate-event-driven, not fundamentals-driven; standalone valuation support is materially below current price.
  • 2022 emergency equity placing at 575p (£350m / 10% of share capital) to fund property-market growth sits oddly against a now-ongoing buyback programme and takeover approach — demonstrates uneven capital planning across cycles 2022-11-16 placing result.
  • Underlying premium-rate index is deteriorating (from +17% in 2022 to -4% in 2025).

Earnings vs. expectations

Across the filings Beazley has consistently met or beaten its own guidance. 2022 CoR guided "high 80s" and delivered. 2023 CoR guided "low 80s" and delivered. 2024 CoR guided "around 80%" despite Helene/Milton (combined net exposure $125-175m) and delivered. In 2025 Beazley upgraded CoR guidance from "mid 80s" (April) to "low 80s" (November) while slightly softening growth guidance to the low end of its range — a quality-over-quantity trade clearly communicated. Pattern: disciplined guidance-setting with modest positive surprise bias on combined ratio; growth guidance is where small misses occur.

Conviction

3 — moderate.

  • Anchors: strong Lloyd's disclosure (clean segmental GWP, rate, portfolio reporting); consistent track record vs. own guidance; well-understood insurance accounting under IFRS 17.
  • Limits: the fair-value call depends almost entirely on whether a takeover closes and on what terms — details are not in the filings supplied. The gap between standalone intrinsic value (~950-1,150p) and current price (1,308p) is wide enough that conviction cannot be higher without the deal consideration disclosure.

Fit for this strategy

Beazley is a quality specialty insurer, but it is not an AI-receiver, is not operationally levered in the way this portfolio prizes, and is currently priced for a takeover rather than priced cheaply on fundamentals. The investor's three-pillar framework (AI beneficiary + operating leverage + valuation discipline) argues against buying new shares at 1,308p.

Filings consulted · 29

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-04-23Result OF Agm2026-04-23_9534808_result-of-agm.md0.30
  2. 2026-04-01Form 8 3 Beazley Plc Amendment Replacing 8788y2026-04-01_9503748_form-8-3-beazley-plc-amendment-replacing-8788y.md0.59
  3. 2026-03-17Notice OF Agm2026-03-17_9478806_notice-of-agm.md0.26
  4. 2026-03-02Dividend Declaration2026-03-02_9454313_dividend-declaration.md0.26
  5. 2025-11-25Trading Statement2025-11-25_9254596_trading-statement.md0.72
  6. 2025-10-06Notice OF Trading Statement Amp Capital Markets Day2025-10-06_9153333_notice-of-trading-statement-amp-capital-markets-day.md0.81
  7. 2025-04-29Trading Statement2025-04-29_8850460_trading-statement.md0.55
  8. 2025-04-22Result OF Agm2025-04-22_8840340_result-of-agm.md0.20
  9. 2025-03-17Notice OF Agm2025-03-17_8783251_notice-of-agm.md0.20
  10. 2024-11-06Trading Statement2024-11-06_8532061_trading-statement.md0.55
  11. 2024-04-29Trading Statement2024-04-29_8160662_trading-statement.md0.38
  12. 2024-04-25Result OF Agm2024-04-25_8157836_result-of-agm.md0.14
  13. 2024-03-20Notice OF Agm2024-03-20_8098505_notice-of-agm.md0.14
  14. 2023-11-30Capital Markets Day Presentation2023-11-30_7913659_capital-markets-day-presentation.md0.43
  15. 2023-11-07Trading Statement2023-11-07_7864216_trading-statement.md0.38
  16. 2023-11-07Notice OF Capital Markets Day2023-11-07_7865680_notice-of-capital-markets-day.md0.43
  17. 2023-07-27Trading Statement For Six Months TO 30 June 20232023-07-27_7657778_trading-statement-for-six-months-to-30-june-2023.md0.21
  18. 2023-05-12Trading Statement2023-05-12_7523984_trading-statement.md0.21
  19. 2023-04-25Result OF Agm2023-04-25_4196_result-of-agm.md0.07
  20. 2023-03-20Notice OF Agm2023-03-20_7479495_notice-of-agm.md0.07
  21. 2022-11-16Beazley Plc Results OF Placing2022-11-16_7374256_beazley-plc-results-of-placing.md0.17
  22. 2022-11-15Beazley Plc Proposed Placing OF Ordinary Shares2022-11-15_7374001_beazley-plc-proposed-placing-of-ordinary-shares.md0.17
  23. 2022-11-11Trading Statement2022-11-11_7336809_trading-statement.md0.21
  24. 2022-05-18Capital Markets Day Presentation2022-05-18_6930878_capital-markets-day-presentation.md0.24
  25. 2022-05-12Notice OF Capital Markets Day2022-05-12_6840604_notice-of-capital-markets-day.md0.24
  26. 2022-05-06Trading Statement2022-05-06_7195041_trading-statement.md0.21
  27. 2022-03-25Result OF Agm2022-03-25_7056500_result-of-agm.md0.07
  28. 2022-02-23Notice OF Agm2022-02-23_6925949_notice-of-agm.md0.07
  29. 2021-11-05Trading Statement2021-11-05_6661569_trading-statement.md0.21

This research note was authored by a large language model after reading 25 regulatory filings published between 2021-11-05 and 2026-04-23. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.